ClinicalTrials.gg
Active, not recruitingNCT05242484DUET-UCUpdated Nov 4, 2026

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of Guselkumab and Golimumab in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 403 sites in 37 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Updated Nov 4, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
577
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing golimumab in Colitis, Ulcerative — none open to participants now, 2 under way, 1 of them phase 3. golimumab · Colitis, Ulcerative.

Enrollment
3rd of 16
577 · median 102
Started
2022
the only one that year
Phase 2
3 of 16
none open now
Registered
16th of 16
by date
Lead sponsor
7 of 16
Janssen Research & Development, LLC

Among the 16 studies testing golimumab in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 3 in phase 2, and was the 16th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

None of the 16 studies testing golimumab in Colitis, Ulcerative is open now. The open studies under Colitis, Ulcerative, anywhere →

About golimumab

golimumab: first FDA approval 2009 (SIMPONI), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing golimumab in Colitis, Ulcerative as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of ulcerative colitis (UC) for at least 3 months prior to baseline
  • Moderately to severely active UC as assessed by the modified Mayo score
  • Demonstrated inadequate response, loss of response, or intolerance to at least one biologic or novel oral with biologic-like activity
  • If female and of , must meet the and reproduction requirements

Exclusion criteria

Exclusion Criteria:

  • Has severe extensive colitis as defined in the protocol
  • Extent of inflammatory disease limited to the rectum
  • Participants with current diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease (CD)
  • Has a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, sinopulmonary infections, bronchiectasis, recurrent renal/urinary tract infections (example, pyelonephritis, cystitis), an open, draining, or infected skin wound, or an ulcer
  • Currently has a or a history of malignancy within 5 years before screening (with the exception of nonmelanoma skin cancer or cervical carcinoma in situ that has been treated with no evidence of recurrence within 12 months of first dose of study intervention)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
577 participants (actual)

Study arms

  • Placebo comparator
    Group 1: Placebo

    Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Drug: Placebo

  • Experimental
    Group 2: Guselkumab

    Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: Guselkumab

  • Experimental
    Group 3: Golimumab

    Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: Golimumab

  • Experimental
    Group 4: JNJ-78934804 (High-dose)

    Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: JNJ-78934804

  • Experimental
    Group 5: JNJ-78934804 (Mid-dose)

    Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: JNJ-78934804

  • Experimental
    Group 6: JNJ-78934804 (Low-dose)

    Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: JNJ-78934804

Interventions

  • BiologicalGuselkumab

    Guselkumab will be administered as subcutaneous injection.

  • BiologicalGolimumab

    Golimumab will be administered as subcutaneous injection.

  • BiologicalJNJ-78934804

    JNJ-78934804 will be administered subcutaneously as per defined regimen.

  • DrugPlacebo

    Placebo will be administered as subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Clinical Remission at Week 48

    Percentage of participants with clinical remission at Week 48 will be reported. Clinical remission based on the modified Mayo subscores.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants with Endoscopic Improvement at Week 48

    Percentage of participants with endoscopic improvement at Week 48 will be reported. Endoscopic improvement at Week 48 based on the Mayo endoscopic subscore.

    Time frame: Week 48

  2. Percentage of Participants with Corticosteroid-free Clinical Remission at Week 48

    Percentage of participants with corticosteroid-free (60-day) clinical remission at Week 48 will be reported.

    Time frame: Week 48

  3. Percentage of Participants with Symptomatic Remission at Week 48

    Percentage of participants with symptomatic remission at Week 48 will be reported. Symptomatic remission at Week 48 based on stool and rectal bleeding symptoms.

    Time frame: Week 48

  4. Percentage of Participants with Combination of Histological Remission and Endoscopic Improvement at Week 48

    Percentage of participants with combination of histological remission and endoscopic improvement at Week 48 will be reported. Histologic remission and endoscopic improvement at Week 48 based on the histologic grading and the Mayo endoscopy subscore.

    Time frame: Week 48

  5. Secondary Comparison: Percentage of Participants with Clinical Remission at Week 48

    Percentage of participants with clinical remission at Week 48 will be reported. Clinical remission based on the modified Mayo subscores will be reported.

    Time frame: Week 48

  6. Percentage of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: Up to Week 48

  7. Percentage of Participants with Serious Adverse Events (SAEs)

    A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

    Time frame: Up to Week 48

  8. Laboratory Parameters Over Time

    Laboratory parameters over time will be reported.

    Time frame: Up to Week 48

  9. Vital Signs Parameters Over Time

    Vital signs parameters over time will be reported.

    Time frame: Up to Week 48

  10. Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

    Time frame: Up to Week 48

  11. Serum Concentrations of Guselkumab Over Time

    Serum concentrations of guselkumab over time will be reported. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive method.

    Time frame: Up to Week 48

  12. Serum Concentrations of Golimumab Over Time

    Serum concentration of golimumab over time will be reported. Serum samples will be analyzed to determine concentrations of golimumab using a validated, specific, and sensitive method.

    Time frame: Up to Week 48

  13. Percentage of Participants with Antibodies to Guselkumab

    Percentage of participants with antibodies to guselkumab will be reported.

    Time frame: Up to Week 48

  14. Titers of Antibodies to Guselkumab

    Titers of antibodies to guselkumab will be reported.

    Time frame: Up to Week 48

  15. Percentage of Participants with Antibodies to Golimumab

    Percentage of Participants with Antibodies to golimumab will be reported.

    Time frame: Up to Week 48

  16. Titers of Antibodies to Golimumab

    Titers of antibodies to golimumab will be reported.

    Time frame: Up to Week 48

  17. Percentage of Participants with Neutralizing Antibodies to Guselkumab

    Percentage of participants with neutralizing antibodies to guselkumab will be reported.

    Time frame: Up to Week 48

  18. Percentage of Participants with Neutralizing Antibodies to Golimumab

    Percentage of participants with neutralizing antibodies to golimumab will be reported.

    Time frame: Up to Week 48

07

Study locations

403 sites

Showing the first 100 of 403 sites across 37 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in May 2025, 31 months.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 31 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Feb 16, 2022
StartActual
Sep 19, 2022
Primary completionActual
May 15, 2025
CompletionEst.
Mar 27, 2029
Results delay requested
May 14, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • The Chaim Sheba Medical Center · Tel HaShomer, Israel
Show 1 removed
  • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • The Chaim Sheba Medical Center · Tel HaShomer, Israel
    Show 1 removed
    • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05242484
Responsible party
Sponsor
First posted
Feb 16, 2022
Start date
Sep 19, 2022
Primary completion
May 15, 2025
Completion
Mar 27, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Guselkumab · Golimumab · JNJ-78934804

Start the discussion